Yarrow Bioscience — Third Quarter 2026 Earnings Summary

Yarrow Bioscience reported a net loss of $9.7 million for the third quarter of 2026, with research and development expenses totaling $5.3 million and general and administrative expenses at $5.5 million. The company holds $268.9 million in cash and cash equivalents as of September 30, 2026, following a $172.5 million public offering completed in September, which extends its operational runway into 2030. Enrollment is ongoing for the Phase 2a portion of the DIRECTION-GD trial evaluating the anti-TSHR antibody YB-101 in patients with Graves' disease, with topline results expected in the second half of 2027. Additionally, data from a partner's Phase 1 trial in thyroid eye disease is anticipated in the same timeframe to inform global development plans.